Suppr超能文献

严重急性呼吸综合征冠状病毒 2 引起的肝损伤及其一些肝生物标志物改变的机制:综述。

Mechanisms of severe acute respiratory syndrome coronavirus-2 induced liver damage and alteration of some liver biomarkers: A review.

机构信息

Department of Medical Biochemistry, College of Medicine and Health Sciences, Ambo University, Addis Ababa, Ethiopia.

出版信息

Medicine (Baltimore). 2023 May 12;102(19):e33517. doi: 10.1097/MD.0000000000033517.

Abstract

The most serious problem for people suffering from severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection is liver damage. The liver is a frequently affected organ due to the metabolizing and detoxifying functions of several endogenous and exogenous molecules. In COVID-19-affected individuals, even moderate loss of hepatic function could dramatically affect the therapeutic efficacy of antiviral drugs metabolized in the liver. The clear mechanism of hepatocellular damage from SARS-CoV-2 infection is not fully understood. The main objective of this review is to identify potential mechanisms of SARS-2 induced liver damage, treatment outcomes in SARS-CoV-2-infected patients, and future direction. Electronic databases including Web of Science, Google Scholar, MEDLINE, Scopus, and Cochrane library were used to systematically search without limitation of publication date and status. Observational, retrospective cohort, prospective case-control, cohort studies, cross-sectional studies, or clinical trials were included. Liver damage in coronavirus patients is characterized by histopathological changes and abnormal elevation of some liver function tests. These abnormalities include elevation of Alanine aminotransferase, Aspartate aminotransferase, Gamma-glutamyl transferase, Alkaline phosphatase, and Serum bilirubin levels. Histopathological changes of the liver might consist of complete or partial thrombosis of the portal and sinusoidal vessels, portal tract fibrosis, and focally markedly enlarged and fibrotic hepatocytes. Understanding the fundamental molecular and immunological processes of COVID-19-related liver injury is essential for the selection of appropriate drugs and the logical development of successful treatment.

摘要

对于严重急性呼吸综合征冠状病毒-2 (SARS-CoV-2) 感染的患者来说,最严重的问题是肝损伤。由于肝脏具有代谢和解毒多种内源性和外源性分子的功能,因此肝脏是经常受到影响的器官。在 COVID-19 患者中,即使是肝功能的中度丧失也可能会极大地影响在肝脏中代谢的抗病毒药物的治疗效果。SARS-CoV-2 感染引起肝细胞损伤的明确机制尚未完全阐明。本综述的主要目的是确定 SARS-CoV-2 引起肝损伤的潜在机制、SARS-CoV-2 感染患者的治疗结果以及未来的方向。本研究无限制地使用了 Web of Science、Google Scholar、MEDLINE、Scopus 和 Cochrane 图书馆等电子数据库进行系统搜索,且不限制出版日期和状态。纳入了观察性、回顾性队列、前瞻性病例对照、队列研究、横断面研究或临床试验。冠状病毒患者的肝损伤表现为组织病理学改变和某些肝功能试验的异常升高。这些异常包括丙氨酸氨基转移酶、天冬氨酸氨基转移酶、γ-谷氨酰转移酶、碱性磷酸酶和血清胆红素水平的升高。肝脏的组织病理学改变可能包括门静脉和窦状血管的完全或部分血栓形成、门管区纤维化和局灶性明显增大和纤维化的肝细胞。了解 COVID-19 相关肝损伤的基本分子和免疫学过程对于选择合适的药物和成功治疗的合理开发至关重要。

相似文献

3
SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19.
J Hepatol. 2020 Oct;73(4):807-816. doi: 10.1016/j.jhep.2020.05.002. Epub 2020 May 11.
6
Potential histopathological and immunological effects of SARS-CoV-2 on the liver.
Braz J Biol. 2022 Sep 5;82:e262008. doi: 10.1590/1519-6984.262008. eCollection 2022.
7
Impaired coagulation, liver dysfunction and COVID-19: Discovering an intriguing relationship.
World J Gastroenterol. 2022 Mar 21;28(11):1102-1112. doi: 10.3748/wjg.v28.i11.1102.
8
Age-adjusted mortality and predictive value of liver chemistries in a Viennese cohort of COVID-19 patients.
Liver Int. 2022 Jun;42(6):1297-1307. doi: 10.1111/liv.15274. Epub 2022 May 5.
9
Histopathological impact of SARS-CoV-2 on the liver: Cellular damage and long-term complications.
World J Gastroenterol. 2024 Jun 14;30(22):2866-2880. doi: 10.3748/wjg.v30.i22.2866.
10
Abnormal liver tests in patients with SARS-CoV-2 or influenza - prognostic similarities and temporal disparities.
JHEP Rep. 2021 Jun;3(3):100258. doi: 10.1016/j.jhepr.2021.100258. Epub 2021 Feb 24.

引用本文的文献

1
Polysaccharides Alleviate Ethanol-Induced Liver Injury by Activating PPAR-α and Inhibiting NLRP-3/Caspase-1-Mediated Pyroptosis.
Food Sci Nutr. 2025 Apr 18;13(4):e70172. doi: 10.1002/fsn3.70172. eCollection 2025 Apr.

本文引用的文献

2
CD209L/L-SIGN and CD209/DC-SIGN Act as Receptors for SARS-CoV-2.
ACS Cent Sci. 2021 Jul 28;7(7):1156-1165. doi: 10.1021/acscentsci.0c01537. Epub 2021 Jun 30.
4
DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist.
PLoS Pathog. 2021 May 20;17(5):e1009576. doi: 10.1371/journal.ppat.1009576. eCollection 2021 May.
5
COVID-19 and liver disease: mechanistic and clinical perspectives.
Nat Rev Gastroenterol Hepatol. 2021 May;18(5):348-364. doi: 10.1038/s41575-021-00426-4. Epub 2021 Mar 10.
6
COVID-19-associated liver injury: from bedside to bench.
J Gastroenterol. 2021 Mar;56(3):218-230. doi: 10.1007/s00535-021-01760-9. Epub 2021 Feb 1.
7
Abnormal liver-related biomarkers in COVID-19 patients and the role of prealbumin.
Saudi J Gastroenterol. 2020 Sep-Oct;26(5):272-278. doi: 10.4103/sjg.SJG_239_20.
8
COVID-19 and the liver.
J Hepatol. 2020 Nov;73(5):1231-1240. doi: 10.1016/j.jhep.2020.06.006. Epub 2020 Jun 15.
9
SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19.
J Hepatol. 2020 Oct;73(4):807-816. doi: 10.1016/j.jhep.2020.05.002. Epub 2020 May 11.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验